ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
298380 | KO
Overview
Corporate Details
- ISIN(s):
- KR7298380007
- LEI:
- Country:
- South Korea
- Address:
- 서울 강남구 봉은사로 456 에이비엘바이오빌딩, 강남구
- Website:
- https://www.ablbio.com
Description
ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-09 00:00 |
주식매수선택권행사
|
Korean | 43.5 KB | ||
| 2025-09-09 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-09-09 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-09-01 00:00 |
투자판단관련주요경영사항(임상시험결과)
|
Korean | 16.4 KB | ||
| 2025-08-26 00:00 |
주식매수선택권부여에관한신고
|
Korean | 17.7 KB | ||
| 2025-08-12 00:00 |
반기보고서 (2025.06)
|
Korean | 1.4 MB | ||
| 2025-08-08 00:00 |
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계…
|
Korean | 21.5 KB | ||
| 2025-07-23 00:00 |
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2025-07-23 00:00 |
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-07-23 00:00 |
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-07-14 00:00 |
전환주식의전환청구권행사
|
Korean | 13.7 KB | ||
| 2025-07-09 00:00 |
투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 기술도입 계약 해지)
|
Korean | 6.5 KB | ||
| 2025-07-04 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 129.2 KB | ||
| 2025-06-11 00:00 |
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계획 (…
|
Korean | 16.9 KB | ||
| 2025-06-04 00:00 |
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계…
|
Korean | 19.5 KB |
Automate Your Workflow. Get a real-time feed of all ABL Bio Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABL Bio Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABL Bio Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
